A comprehensive portal site for Medical Innovation Support Office (MEDISO).Medical Innovation Support Office

Akiko Yamamoto

Nissan Chemical Corporation
Risk Management ＆Compliance Office
Risk Management Department

Graduated from the Department of Pharmacy at Kyoritsu Collage of Pharmacy (currently Keio University) and received a Ph.D. from Gifu Pharmaceutical University. Engaged in work related to each process of pharmaceutical life cycle (research and development, sales promotion, licensing/alliance, quality assurance and Good Vigilance Practice(GVP)) at Nissan Chemical Corporation. Especially, as the corporate quality assurance department leader, managed the company's pharmaceutical quality system, and maintained and improved appropriate quality assurance systems for API manufacturing sites, manufacturing contractors, and contract testing facilities. Specifically, provided support during FDA inspections and global pharma quality audits, and advised on improvements and response policies for issues raised. Also has experience in implementing regulations and change processes when adding starting material, intermediate and API manufacturing sites, and testing facilities. In addition, has reviewed documents such as license and quality assurance-related contract contents, change applications and master files to be submitted to authorities.

Hirokazu Yamaguchi

Tomokatsu Hongo

Keio Innovation Initiative, Inc
Corporate Officer

Ph.D. in Biological Chemistry from Nagoya University. At Summit Pharmaceuticals International Corporation, I was engaged in VC fund management, investment and sales support for bio-ventures, and domestic sales agency business for overseas bio-ventures. In 2016, I joined Keio Innovation Initiative (KII) as an investment manager in the medical and health field. I have been investing in drug discovery, regenerative medicine, and medical device ventures by leveraging his business experience in the pharmaceutical industry and career as a researcher, and providing a wide range of hands-on support, not only in terms of funding, but also in business development.

Kazuhiro Kanmuri

Inter-Professional Inc.

He engaged in pharmaceutical research and development for more than 25 years. He has gained experience in Japan and in the US development organization of Daiichi Sankyo Co., Ltd., Pfizer Inc., and CRO/consulting organizations, and has been deeply involved in strategic/regulaotry planning of clinical developmentincluding overseas organizations. His specialized fields are extensive, which include company clinical trials and investigator-initiated clinical trials, organization management, strategy development, and clinical trial operation/implementation, safety and pharmacovigillance, and he is active in the academic area of regulatory science. Currently, he engages in the consulting business as an expert in clinical development/organization and human resources development through the corporation that he established by himself and specialized CRO. In addition to being the incumbent, he concurrently served as a visiting lecturer of an academia organization, and he belongs to DIA Japan, an industry association of the pharmaceutical industry, and served as the Vice Program Committee Chair of the DIA Japan annual convention in 2018.

Satoshi Ogawa

TMI Associates Partner (Attorney)

Satoshi Ogawa, Ph.D., is a partner at TMI Associates specializing in life sciences and healthcare. After earning his Ph.D. in Life Sciences from Kyoto University, he joined TMI Associates as an attorney. Following a three-year secondment at a law firm in New Delhi, India, he has been based at TMI’s Kyoto Office since 2019. Dr. Ogawa advises both Japanese and international clients on cutting-edge technologies, including regenerative medicine, digital health, and AI-driven healthcare solutions. His work covers startup support, patent licensing, industry–academia collaboration, regulatory compliance, and intellectual property disputes. He works extensively with universities, startups, pharmaceutical and medical device companies, venture capital firms, and public institutions. He also serves as an advisor to BioCommunity Kansai (BiocK) and HVC KYOTO, and contributes to conflict-of-interest (COI) committees and institutional review boards (IRBs). Dr. Ogawa is passionate about advancing innovation and helping clients navigate complex legal and regulatory challenges in the life science ecosystem. His publications include “Startup Intellectual Property and Legal Guidebook – Key Points for Early-Stage Bio and Life Science Ventures” (METI-Kansai) and “Healthcare Business Legal Consultation Handbook” (Chuokeizai-sha).